Creative Medical Reports Positive Interim Data for CELZ-201 Olastrocel
ByAinvest
Tuesday, Jan 13, 2026 9:31 am ET1min read
CELZ--
Creative Medical Technology Holdings reported positive 180-day follow-up data from its ADAPT clinical trial for CELZ-201 (Olastrocel), a cell therapy for chronic lower back pain. The study showed statistically significant improvements in functional disability and pain, confirming durable efficacy and an excellent safety profile. The trial was completed with a favorable safety profile and no significant adverse events.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet